Search PubMed⌕ Search

Biomedical subjects

M Izuo

Publications and source records attributed to M Izuo.

At least 109 records · Page 6Linked to original sources
PubMed1984

Breast carcinoma arising in cystosarcoma phyllodes: report of a case with a review of the literature.

An extremely rare case of coexistent carcinoma arising in a cystosarcoma phyllodes of the breast is reported. A 41-year-old Japanese woman was referred with a lump in the right breast. A tumor measuring 5.6 X 3.6 X 3.2 cm was removed by local excision. Histological examination revealed foci of papillo-tubular carcinoma within the benign cystosarcoma phyllodes. Radical mastectomy was performed and the axillary lymph nodes showed no metastasis. While 22 cases of coexistent carcinoma and cystosarcoma phyllodes in the same breast have been reported, in only nine of those cases, the carcinomas including this case have developed within the cystosarcoma phyllodes.

Adult↗
PubMed1984

[Clinicopathological study of breast cancers associated with other primary cancers].

Thirty six cases of breast cancer associated with other primary cancer were found out among 1160 patients with primary breast cancer. They consisted of 6 synchronous combination and 30 metachronous, in which 23 were detected as the first lesion and 7 were the second. The other organs involved by cancer were the stomach (11), thyroid (9), colon or rectum (5), uterus (3), and others (8). Although the TNM stage of the breast cancer was mostly in stage I or II (91.6%), the prognosis was poor in the metachronous cases, depending on the nature of the second primary cancer. It is important to detect and treat a second primary cancer in the early stage.

Adult↗
PubMed1984

[Some problems in the treatment of early breast cancer].

In Japan, most surgeons regard Stage I cancer of TNM system as "early breast cancer". Modified radical mastectomy is generally performed for the Stage I cancer. However, most recurrence sites of those cases, even in Stage I cancer, are distant organs such as lung, bone, etc. Corresponding to this, the Stage I cancer has blood vessel invasion in some cases and the incidence is almost 10%. Consequently, postoperative adjuvant chemotherapy is required in such cases. We have experienced several cases of small (less than or equal to 5 mm) non-infiltrating carcinoma detected only by microcalcification on mammogram. In such cases, a quadrantectomy and further follow-up are indicated as an appropriate treatment at present. Thus, even the treatment for the early breast cancer should be applied a wide-varied policy.

Adult↗
PubMed1983

[Effect of medroxyprogesterone acetate (MAP) and vitamin C on DMBA induced rat mammary cancer in relation to estrogen receptor(ER)].

In mature male and female SD rats, the anti-weight gain effect of durabolin plus vitamin C or vitamin C alone was statistically significant compared to durabolin-treated and control rats. The anti-tumor and anti-weight gain effects of MAP plus vitamin C on DMBA-induced rat mammary cancer were compared with those of MAP and vitamin C in relation to ER. An anti-tumor effect was noted in the MAP treated groups, irrespective of the ER status; it was more pronounced in the MAP (100 mg/kg) plus vitamin C treated group with ER+tumors. Among the ER+tumor groups, weight gain was remarkable in the MAP-treated (20 mg/kg) animals; an anti-weight gain effect was seen in the MAP (20 mg/kg) plus vitamin C group.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1983

[Breast cancer and estrogen receptors: its clinical significance and problems].

The clinical usefulness of estrogen receptor (ER) assays in the management of breast cancer has been established. However, several problems remained. In this paper, the problematic aspects of ER such as the molecular forms, inter-site variations, relationships to histological pattern, with regard to the effectiveness of chemotherapy and to prognosis, and ER in male breast cancer, are reviewed and discussed.

Aged↗
PubMed1983

[Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].

The clinical efficacy of two combination chemotherapies, "CAF" (cyclophosphamide, adriamycin, fluorouracil) and "CMcF" (cyclophosphamide, mitomycin C, fluorouracil) were evaluated on the patients with disseminated breast cancer. Two dosage levels were prepared for each combination. After the investigators decided the dosage levels for the patients, patients were assigned to either combination chemotherapy, CAF or CMcF. Among those patients, 138 cases were evaluable. The objective response rates according to "Assessment Criteria of Therapeutic Effects on Advanced or Recurrent Breast Cancer" by Japan Breast Cancer Society were as follows; High dose schedule: CAF 48.4% (15/31) CMcF 40.9% (9/22) Low dose schedule: CAF 31.7% (13/41) CMcF 15.9% (7/44) In both dosage levels, CAF produced higher response rate than CMcF: The toxicities commonly encountered in all treatment groups were anorexia, nausea and vomiting, as well as leucopenia. Alopecia in CAF and thrombocytopenia in CMcF were characteristic side effects.

Adult↗
PubMed1983

[Hormone receptors: clinical significance and problems in the treatment of breast cancer].

ER and PgR were measured by sucrose gradient centrifugation in 212 cases of breast cancer. Positive rates of ER and PgR were 56% and 39%. Close relationship between receptor status in general and response to endocrine therapy was observed. In the respect of molecular forms of ER, however, the cases having receptor of "4S only" were less responsive. Inter-site variation within large tumor was examined and it was confirmed in almost 30% of series. To avoid such misjudge, tissue sliced at largest cross-section was recommended. As for prognosis of breast cancer, ER+ cases showed more favourable postoperative course in disease-free interval and also in interval from recurrence to death.

Adult↗
PubMed1982

[Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].

The antitumor effect and side effects of oral high-dose Medroxyprogesterone acetate (MPA) therapy were studied in 110 patients with advanced or recurrent breast cancer. MPA in 200 mg tablets was consecutively administered at a daily dose of 600, 800, 1,000, 1,200, 1,600, 1,800 or 2,400 mg. The overall response rate was 32/110 (29.1%), and the highest response rate was obtained in the 1,200 mg group (38.2%). The response rate by the site of lesion was higher in the soft tissues and also in bone metastases. Side effects such as moon face, vaginal spotting and abnormal glucose tolerance was mild and tolerable. Accordingly, from the antitumor effect and side effects, the optimal dose was considered to be 1,200 mg a day. Furthermore, as MPA therapy increases appetite and body weight of patients without causing myelopoietic depression, this drug could be used successfully in combination with other chemotherapeutic agents.

Adult↗
PubMed1982

[Effect of levamisole hydrochloride on advanced and recurrent breast cancer--LMS randomized controlled study of a group responding to CAF (cyclophosphamide, adriamycin, and 5-FU) therapy].

The effect of levamisole HCL on advanced and recurrent breast cancer was investigated cooperatively by a randomized controlled study using envelope method. Patients with advanced and recurrent breast cancer who had showed either complete response or partial response to the previous CAF therapy (cyclophosphamide 100 mg/body/day p.o. from day 1 to 14, adriamycin 30 mg/body/day i.v. on day 1 and 8, 5-FU 500 mg/body/day i.v. on day 1 and 8) were entered in this study and divided randomly into a control group and a levamisole group. No further treatment was given to patients of the control group until they fell into progressive disease. Patients of the levamisole group were given the drug at a daily dose of 150 mg for 3 consecutive days every fortnight. Fifty-nine cases were entered in this protocol, but 9 cases of them were ruled out as exclusions or dropouts. Therefore, the number of eligible cases was 31 in the levamisole group and 19 in the control group. Both the duration of remission and the survival time were significantly (p less than 0.05) prolonged in the levamisole group compared with the control group. There was no difference in side effects between these two groups.

Antineoplastic Agents↗
PubMed1982

[Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-5-FU combination therapy with or without levamisole. 1].

A randomized controlled study by envelope method was carried out with the purpose of evaluating effects and side effects of levamisole in patients with resectable stomach cancer. The patients were randomly allocated to the treatment either with control or levamisole according to the indication of the envelope opened at least 3 days prior to surgery. The control group was treated with Mitomycin C (day 0, 20 mg day 1, 10 mg, one shot i.v.) and 5-FU(150 mg/day, p.o.). The levamisole group was treated with Mitomycin C, 5-FU and levamisole. Levamisole was administered at a daily dose of 150 mg for 3 consecutive days before surgery, and the 3 consecutive days administration schedule was repeated every fortnight for one year after surgery. Four hundred and forty-six patients were entered in this trial. However, with the exclusion of 104 patients as exceptions and dropouts, the total eligible patients were 342, consisting of 167 in the control group and 175 in the levamisole group. The effects were evaluated by comparing the disease-free interval or the survival time of both groups. There was no significant difference in the disease-free interval and survival. In this study, we have not yet reached the conclusion that levamisole is effective in prolonging disease-free interval and survival time, because high survival rates are still maintained in both groups for 2 years after surgery. The final conclusion would be drawn with the follow-up results in the future.

Adjuvants, Immunologic↗
PubMed1982

[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].

Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer. According to the response criteria for advanced breast cancer by the Japan Mammary Cancer Society, complete response was obtained in 6 cases and partial response in 19 and an overall effective rate was 29.4% (25/85). In terms of efficacy classified by metastatic lesion, the effective rate was more than 40% in skin and subcutaneous tissue, and lymph nodes, but if was low in bone metastases. Alopecia, leukopenia, nausea and vomiting were observed very frequently as side effects, but they disappeared within three weeks, except alopecia. CAF therapy is considered to be useful in the treatment of advanced and recurrent breast cancer.

Adult↗
PubMed1982

[Preoperative immunochemotherapy for gastric cancer patients--immunomodulating effect of levamisole and lentinan on cell-mediated immunity and regional lymph node].

The effects of two immunomodulators, levamisole and lentinan, on cell-mediated immunity and regional lymph nodes of patients with gastric cancer were studied, including reference to some literature. 1) The counts of active T-cells and total T-cells in the peripheral blood showed a tendency of increase after administration of levamisole. 2) PHA lymphocyte blastoformation in the peripheral blood with and without autoserum was enhanced by the administration of levamisole and lentinan. 3) The percentage of active T-cells and PHA lymphocyte blastoformation in the peripheral blood with and without autoserum in proximal regional lymph nodes were increased by the administration of levamisole and lentinan. 4) The percentage of active T-cells and PHA lymphocyte blastoformation in the peripheral blood with and without autoserum in distal regional lymph nodes were increased by the administration of levamisole. 5) Postoperative depression of PHA and PPD skin tests was enhanced by preoperative administration of levamisole, and that of PHA skin test was enhanced by the administration of lentinan.

Adjuvants, Immunologic↗
PubMed1981

Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.

Medroxyprogesterone acetate (MAP) in the treatment of advanced breast cancer has been regarded as a minor agent according to the previous reports when used at low doses (less than 500 mg/day). High doses of more than 500 mg which have come into use since 1973 give a response rate of over 40%, but sometimes cause gluteal abscess or induration because of daily intramuscular injections. In order to administer easily and to avoid the side effect, we have attempted to use oral administration in a daily dose of 1200 mg (400 mg X 3). Of those 20 patients treated with oral high-dose MAP, 1 showed complete response, 6 showed partial response, 7 no change, and 6 progressive disease. As for site of lesion, 4 out of 6 (67%) in skin and 4 out of 16 (25%) in bone responded. Neither severe side effects nor abnormal laboratory data were seen. Then, we examined the blood levels of MAP in vivo by RIA in 9 patients. The blood level of MAP reached 39-250 ng/ml in 3 days and was maintained at least over 50 ng/ml for 1 or 2 months of continuous administration. Subsequently, we examined the effects of MAP on binding to ER in vitro. The inhibition of binding of estradiol-17 beta to ER was about 60% at 10(-5) M MAP. The blood level of 50 ng/ml in vivo corresponds to about 1.3 X 10(-5) M.

Administration, Oral↗